免疫性血小板減少症治療薬の世界市場

免疫性血小板減少症治療薬の世界市場は2030年までに35億米ドルに達する

2023年に33億米ドルと推定される免疫性血小板減少症治療薬の世界市場は、2030年には35億米ドルに達し、分析期間2023-2030年のCAGRは1.0%で成長すると予測されます。本レポートで分析したセグメントの1つである副腎皮質ステロイドは、CAGR 0.9%を記録し、分析期間終了時には18億米ドルに達すると予測されます。静注用免疫グロブリンセグメントの成長率は、分析期間中CAGR 1.4％と推定されます。

米国市場は8億9,160万米ドルと推定、中国はCAGR 1.9％で成長予測

米国の免疫性血小板減少症治療薬市場は2023年に8億9,160万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 1.9%で推移し、2030年には6億2,500万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.6%と0.9%と予測されています。欧州では、ドイツがCAGR約0.6%で成長すると予測されています。

世界の免疫性血小板減少症治療薬市場- 主要動向と促進要因まとめ

免疫性血小板減少症（ITP）は、正常な血液凝固に不可欠な血小板を、身体の免疫系が誤って攻撃・破壊することを特徴とする自己免疫疾患です。この病態は、過剰なあざや出血を引き起こし、重症の場合は生命を脅かす出血を起こすこともあります。ITPの管理には、血小板数の増加と出血エピソードの予防を目的とした様々な治療アプローチが含まれます。治療の第一選択としては、免疫反応を抑制するコルチコステロイドと、血小板値を一時的に上昇させる免疫グロブリン静注（IVIG）が一般的です。これらの初期治療に反応しない患者には、B細胞を標的とするモノクローナル抗体であるリツキシマブや、血小板産生を刺激するエルトロンボパグやロミプロスチムのようなトロンボポエチン受容体作動薬（TPO-RA）などの第二選択治療が一般的に使用されます。これらの薬剤は、より効果的で的を絞ったITP治療の選択肢を提供し、ITP治療に革命をもたらしました。

最近のITP病態生理の理解に関する動向は、より新しい薬剤や治療戦略の開発につながり、より良好な病勢コントロールと患者の転帰の改善に希望をもたらしています。研究は、血小板の破壊に関与する特定の免疫経路と細胞標的の同定に焦点を当てています。その結果、血小板破壊につながる免疫過程を阻害することで効果を発揮する脾臓チロシンキナーゼ（SYK）阻害剤フォスタマチニブなどの新規治療薬が開発されました。もう一つの有望な研究分野は、免疫系をより正確に調節し、広範な免疫抑制に伴う副作用のリスクを軽減できる生物学的製剤の使用です。さらに、個別化医療の進歩により、個々の患者の特性や疾患の重症度に基づいた、よりオーダーメイドの治療アプローチが可能となり、ITP管理の有効性が高まっています。

免疫性血小板減少症治療薬市場の成長は、自己免疫疾患の有病率の増加、ITPに対する認識と診断の高まりなど、いくつかの要因によってもたらされます。薬剤開発における技術的進歩や疾患メカニズムに対するより深い理解が、より的を絞った効果的な治療法のイントロダクションつながっています。また、患者やヘルスケアプロバイダーがより新しく効果的な治療法を選択するため、専門的で高度な治療を求める消費者の行動も市場の成長を支えています。さらに、製薬企業による研究開発への多額の投資と規制当局からの支援が、革新的なITP治療薬の承認と商業化を促進しています。特に新興市場におけるヘルスケアインフラの拡充は、先進治療へのアクセスを向上させ、市場の成長をさらに促進しています。これらの要因が相まって、ITP市場はダイナミックに拡大しており、ITPに罹患した患者の予後と生活の質の向上を目指しています。

調査対象企業の例（全51件）

• AInos Inc.
• Amgen Inc.（Nplate）
• CSL Behring US Medical Affairs
• F. Hoffmann-La Roche Ltd
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC
• Kyowa Hakko Kirin Co., Ltd
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.
• Rigel Pharmaceuticals, Inc.
• Sandoz Canada Inc.
• Shionogi & Co., Ltd.
• Sobi（Doptelet）
• Teva Active Pharmaceutical Ingredients（A Division of Teva Pharmaceutical Industries Ltd.）
• Viatris Inc.;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Immune Thrombocytopenia Drugs Market to Reach US$3.5 Billion by 2030

The global market for Immune Thrombocytopenia Drugs estimated at US$3.3 Billion in the year 2023, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 1.0% over the analysis period 2023-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 0.9% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Intravenous Immunoglobulins segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$891.6 Million While China is Forecast to Grow at 1.9% CAGR

The Immune Thrombocytopenia Drugs market in the U.S. is estimated at US$891.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$625.0 Million by the year 2030 trailing a CAGR of 1.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 0.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.6% CAGR.

Global Immune Thrombocytopenia Drugs Market - Key Trends and Drivers Summarized

Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by the body's immune system mistakenly attacking and destroying platelets, which are essential for normal blood clotting. This condition can lead to excessive bruising, bleeding, and in severe cases, life-threatening hemorrhages. The management of ITP involves a variety of therapeutic approaches aimed at increasing platelet count and preventing bleeding episodes. The first line of treatment typically includes corticosteroids, which help suppress the immune response, and intravenous immunoglobulin (IVIG), which temporarily raises platelet levels. For patients who do not respond to these initial treatments, second-line therapies such as rituximab, a monoclonal antibody that targets B cells, and thrombopoietin receptor agonists (TPO-RAs) like eltrombopag and romiplostim, which stimulate platelet production, are commonly used. These drugs have revolutionized the treatment landscape of ITP by providing more effective and targeted options for managing the disease.

Recent advancements in the understanding of ITP pathophysiology have led to the development of newer drugs and treatment strategies that offer hope for better disease control and improved patient outcomes. Research has focused on identifying specific immune pathways and cellular targets involved in the destruction of platelets. This has led to the development of novel therapies such as fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, which works by interfering with the immune processes that lead to platelet destruction. Another promising area of research is the use of biologics that can modulate the immune system more precisely, reducing the risk of side effects associated with broad immunosuppression. Additionally, advances in personalized medicine are enabling more tailored treatment approaches based on individual patient characteristics and disease severity, enhancing the efficacy of ITP management.

The growth in the immune thrombocytopenia drugs market is driven by several factors, including the increasing prevalence of autoimmune disorders and the rising awareness and diagnosis of ITP. Technological advancements in drug development and a better understanding of the disease mechanisms have led to the introduction of more targeted and effective therapies. Consumer behavior towards seeking specialized and advanced treatments has also supported market growth, as patients and healthcare providers opt for newer, more effective treatment options. Additionally, significant investments in research and development by pharmaceutical companies and support from regulatory bodies have facilitated the approval and commercialization of innovative ITP therapies. The expansion of healthcare infrastructure, particularly in emerging markets, has increased access to advanced treatments, further driving market growth. These factors collectively ensure a dynamic and expanding market for immune thrombocytopenia drugs, aiming to improve patient outcomes and quality of life for those affected by this challenging condition.

Select Competitors (Total 51 Featured) -

• AInos Inc.
• Amgen Inc. (Nplate)
• CSL Behring US Medical Affairs
• F. Hoffmann-La Roche Ltd
• Fresenius Kabi AG
• Hikma Pharmaceuticals PLC
• Kyowa Hakko Kirin Co., Ltd
• Novartis Pharmaceuticals Corporation
• Pfizer Inc.
• Rigel Pharmaceuticals, Inc.
• Sandoz Canada Inc.
• Shionogi & Co., Ltd.
• Sobi (Doptelet)
• Teva Active Pharmaceutical Ingredients (A Division of Teva Pharmaceutical Industries Ltd.)
• Viatris Inc.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Immune Thrombocytopenia Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rise in Autoimmune Disorders Globally Increases Demand for ITP Therapeutics
  • Corticosteroids Remain the Drugs of Choice for Management of Acute ITP
  • Aging Population, a Key Demographic Growth Driver
  • Drug-induced Thrombocytopenia Rises in Prevalence
  • Advances in Biological Therapies Offer New Hope for ITP Patients
  • Role of Genetic Research in Understanding and Treating ITP
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Immune Thrombocytopenia Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Intravenous Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Intravenous Immunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Thrombopoietin Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Thrombopoietin Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Thrombopoietin Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Thrombocytopenia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Acute Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Acute Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Acute Immune Thrombocytopenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Chronic Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Chronic Immune Thrombocytopenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Chronic Immune Thrombocytopenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: World 16-Year Perspective for Specialty Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: World 16-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• JAPAN
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• CHINA
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 61: China 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 64: China 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 67: China 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• EUROPE
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• FRANCE
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 82: France 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 85: France 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 88: France 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• GERMANY
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• INDIA
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 166: India 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 169: India 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 172: India 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Immune Thrombocytopenia Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030
• AFRICA
  • Immune Thrombocytopenia Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Immune Thrombocytopenia Drugs by Treatment - Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Immune Thrombocytopenia Drugs by Treatment - Percentage Breakdown of Value Sales for Corticosteroids, Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists and Other Thrombocytopenia Drugs for the Years 2014, 2024 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Immune Thrombocytopenia Drugs by Indication - Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Immune Thrombocytopenia Drugs by Indication - Percentage Breakdown of Value Sales for Acute Immune Thrombocytopenia and Chronic Immune Thrombocytopenia for the Years 2014, 2024 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Immune Thrombocytopenia Drugs by End-Use - Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Immune Thrombocytopenia Drugs by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Specialty Centers End-Use and Research & Academic Institutes End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION